Esperion is best known for initial development of ApoA-1 Milano protein as an atherosclerosis therapy.
The lipoprotein enhanced the ability of HDL, or “good” cholesterol to usher fat out of the arteries and into the liver for excretion leading to the purchase of Esperion Therapeutics, the tiny company that had produced recombinant Apo-A1 Milano, by Pfizer for $1.3 billion.
Trius Therapeutics | The Medical Letter on Drugs and Therapeutics | Journal of Pharmacology and Experimental Therapeutics | Journal of Manipulative and Physiological Therapeutics | Esperion Therapeutics | Acorda Therapeutics |